指南与共识炎症性肠病

炎症性肠病先进治疗开始前评估与疫苗接种的共识声明

Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.
指南 / 共识 · Aliment Pharmacol Ther · 2024-10-10

该共识采用改良德尔菲法,针对炎症性肠病(IBD)启动单克隆抗体、JAK抑制剂或S1P调节剂前的评估与疫苗接种形成8条声明,其中6条达成共识。声明涵盖感染病筛查、疫苗接种方案修订,以及JAK抑制剂前的恶性肿瘤、心血管和血栓栓塞风险评估,S1P调节剂前的心脏和眼科评估。共识旨在整合为单一综合文件以减少先进治疗相关并发症。

要点

  • 启动JAK抑制剂前需进行恶性肿瘤、心血管及血栓栓塞风险评估。
  • 启动S1P调节剂前需进行心脏和眼科评估。
  • 共识建立了先进治疗前感染病筛查及修订的疫苗接种方案。

核心结论

  • 共识声明将当前IBD先进治疗的疫苗接种与评估整合为单一综合文件,可能减少先进治疗相关并发症。
  • 共识过程中识别的知识空白将提供进一步研究机会。

研究设计与样本

  • 采用改良德尔菲法,代表对声明可接受性进行匿名投票,投票在共识讨论前后各进行。
  • 检查了关于启动先进IBD治疗前疫苗接种和评估建议的文献、指南和药品信息。

主要发现

  • 共制定8条声明,涉及感染病筛查、疫苗接种以及启动JAK抑制剂和S1P调节剂前的评估。
  • 其中6条声明获得同意。
  • 建立了先进治疗前感染病筛查,并修订了疫苗接种方案。
  • 启动JAK抑制剂前需进行恶性肿瘤、心血管和血栓栓塞风险评估。
  • 启动S1P调节剂者需进行心脏和眼科评估。

局限性

  • 共识过程中识别的知识空白将提供进一步研究机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential. AIMS: To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine-1-phosphate (S1P) modulators for IBD. METHODS: We examined literature, guidelines and drug product information regarding vaccination and assessment recommendations for initiating advanced IBD therapies. Using a modified Delphi approach, delegates voted anonymously on the acceptability of these statements prior to and following consensus discussion. RESULTS: We developed eight statements on the domains of infectious diseases screening, vaccinations and assessments prior to commencing JAK inhibitors and S1P modulators. Six statements received agreement. Pre-advanced therapy screening for infectious diseases was established, and the vaccination protocol was revised. Malignancy, cardiovascular and thromboembolic risk assessments are necessary before initiating JAK inhibitors. Those starting S1P modulators need cardiac and ophthalmic assessments. CONCLUSIONS: These consensus statements combine vaccination and assessments on the currently available advanced therapies for IBD as a single comprehensive document that may reduce IBD complications associated with use of advanced therapies. Knowledge gaps identified during the consensus process will provide further research opportunities.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Leong RW, Sakiris A, Arzivian A, et al. Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases. Aliment Pharmacol Ther. 2024. PMID: 39387155. doi:10.1111/apt.18318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。